KRONOS WORLDWIDE INC (KRO)       11.75  -0.18 (-1.51%)

11.75  -0.18 (-1.51%)

US50105F1057 - Common Stock - After market: 11.75 0 (0%)


Fundamental Rating

6

Overall KRO gets a fundamental rating of 6 out of 10. We evaluated KRO against 123 industry peers in the Chemicals industry. While KRO has a great health rating, its profitability is only average at the moment. A decent growth rate in combination with a cheap valuation! Better keep an eye on KRO.




Profitability

Profitability Rating

4

KRO has a good Piotroski-F score of 7.00. This indicates a good health and good profitability for KRO.
KRO's Return On Assets of 8.03% is in line with the rest of the industry. The industry average Return On Assets is 7.72%.

KRO has a Return On Equity of 17.75%. This is comparable to the industry average of 19.26%.
KRO's Profit Margin of 7.49% is worse than the rest of the industry. The industry average Profit Margin is 8.37%.
VS Industry

ROA (8.03%) VS Industry: 55% outperformed.

0.04
624.60

ROE (17.75%) VS Industry: 49% outperformed.

0.05
225.47

Profit Margin (7.49%) VS Industry: 38% outperformed.

0.06
85.23

Valuation

Valuation Rating

7

With a Price/Earnings Ratio of 8.64, the valuation of KRO can be described as very reasonable.
KRO's Price/Earning Ratio is a bit cheaper than the industry average which is at 12.52.
KRO's low PEG Ratio, which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
When comparing the price book ratio of KRO to the average industry price book ratio of 2.22, KRO is valued rather cheaply.

Compared to an average industry Enterprise Value to EBITDA ratio of 9.37, KRO is valued rather cheaply
With a price book ratio of 1.54, KRO is valued correctly.
The Forward Price/Earnings Ratio of 29.33 indicates a quite expensive current valuation of KRO.
VS Industry

Price/Earnings (8.64) VS Industry: 69% outperformed.

602.17
2.06

Price/Book (1.54) VS Industry: 73% outperformed.

764.36
0.03

Enterprise Value/ EBITDA (5.3) VS Industry: 74% outperformed.

13,692.96
1.68

Growth

Growth Rating

4

KRO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 72.15%, which is quite impressive.
KRO shows a strong growth in Earnings Per Share. Measured over the last 5 years, the EPS has been growing by 22.87% yearly.
The Revenue has grown by 12.13% in the past year. This is quite good.
The Earnings Per Share is expected to grow by 5.83% on average over the next 5 years.

KRO shows a small growth in Revenue. Measured over the last 5 years, the Revenue has been growing by 7.29% yearly.
The Revenue is expected to decrease by -1.34% on average over the next 5 years.
When comparing the EPS growth rate of the last years to the growth rate of the upcoming 5 years, we see that the growth is decreasing.
The Revenue growth is decreasing: in the next 5 years the growth will be less than in the last years.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPS22.87% -17.89% 72.15% -1.75% -36.06% 5.83% N/A
Revenue7.29% 5.28% 12.13% 4.44% -4% -1.34% N/A

Health

Health Rating

7

A Current Ratio of 3.81 indicates that KRO has no problem at all paying its short term obligations.
When comparing the Current Ratio to an average industry Current Ratio of 2.07, KRO is better placed than the average industry peer to meet its short term obligations.
KRO has a Quick Ratio of 2.26. This indicates that KRO is financially healthy and has no problem in meeting its short term obligations.
KRO is better placed than average in its industry to meet its short term obligations. Its Current Ratio is much better than the industry average of 1.33.

KRO has a good Piotroski-F score of 7.00. This indicates a good health and good profitability for KRO.
The Debt to Equity ratio of KRO is in line with the industry averages.
KRO has an Altman-Z score of 2.73. This is not the best score and indicates that KRO is in the grey zone with still only limited risk for bankruptcy at the moment.
The Altman-Z score is in line with the industry averages, which is at 2.69.
VS Industry

Debt/Equity (0.44) VS Industry: 57% outperformed.

19.13
0.00

Quick Ratio (2.26) VS Industry: 75% outperformed.

0.01
65.94

Current Ratio (3.81) VS Industry: 80% outperformed.

0.01
65.94

Altman-Z (2.73) VS Industry: 51% outperformed.

-4,753.15
145.35

Dividend

Dividend Rating

8

KRO has a Yearly Dividend Yield of 6.97%, which is a nice return.
Compared to an average industry Dividend Yield of 2.22, KRO pays a better dividend. On top of this KRO pays more dividend than 88% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.41, KRO pays a better dividend.
KRO has paid a dividend for at least 10 years, which is a reliable track record.

The dividend of KRO has a limited annual growth rate of 1.92%.
KRO pays out 55.51% of its income as dividend. This is a bit on the high side, but may be sustainable.
The Dividend Rate of KRO has been growing, while earnings will be declining. This means the dividend growth is most likely not sustainable.
VS Industry

Dividend Yield (6.97%) VS Industry: 88% outperformed.

0.30
22.94

KRONOS WORLDWIDE INC11.75

NYSE:KRO (2/3/2023, 7:04:00 PM)-0.18 (-1.51%)

After market: 11.75 0 (0%)

Chartmill FA Rating
GICS Sector Materials
GICS IndustryGroup Materials
GICS Industry Chemicals
Earnings (Last) 11-02 2022-11-02/amc Earnings (Next) 03-07 2023-03-07/amc
Inst Owners 16.07% Inst Owner Change -0.19%
Ins Owners 0.1% Ins Owner Change 1.78%
Market Cap 1.36B Analysts 46
Price Target 10.2 (-13.19%)

Dividend
Industry RankSector Rank
Dividend Yield 6.97%
Dividend Growth(5Y) 1.92% DP 55.51%
Div Incr Years 1 Div Non Decr Years 10
Ex-Date N/A

Surprises & Revisions
EPS beat(2) 1 Avg EPS beat(2) 22.26%
Min EPS beat(2) -17.49% Max EPS beat(2) 62.02%
EPS beat(4) 3 Avg EPS beat(4) 34.15%
Min EPS beat(4) -17.49% Max EPS beat(4) 83.35%
Revenue beat(2) 1 Avg Revenue beat(2) -1.42%
Min Revenue beat(2) -6.11% Max Revenue beat(2) 3.27%
Revenue beat(4) 3 Avg Revenue beat(4) 1.99%
Min Revenue beat(4) -6.11% Max Revenue beat(4) 10.58%
PT rev (1m) 0% PT rev (3m) 3.45%
EPS NQ rev (1m) 0% EPS NQ rev (3m) -800%
EPS NY rev (1m) 0% EPS NY rev (3m) -16.74%
Revenue NQ rev (1m) 0% Revenue NQ rev (3m) -28.45%
Revenue NY rev (1m) 0% Revenue NY rev (3m) -4.83%

Valuation
Industry RankSector Rank
PE 8.64
Fwd PE 29.33
P/S 0.65
P/FCF 18.71
P/OCF 9.72
P/B 1.54
P/tB 1.54
EV/EBITDA 5.3
EPS(TTM) 1.36 EY 11.57%
EPS(NY) 0.4 Fwd EY 3.41%
FCF(TTM) 0.63 FCFY 5.34%
OCF(TTM) 1.21 OCFY 10.29%
SpS 18.05 BVpS 7.61
TBVpS 7.61 PEG (NY) N/A
PEG (5Y) 0.38

Profitability
Industry RankSector Rank
ROA 8.03%
ROE 17.75%
ROIC 10.17%
ROICexc 12.88%
ROICexgc 12.88%
OM 10.26%
PM 7.49%
GM 22.67%
ROICexgc(3y) 8.59% ROICexcg growth 3Y -17.2%
ROICexcg growth 5Y 8.73% ROICexc(3y) 8.59%
ROICexc growth 3Y -17.2% ROICexc growth 5Y 8.73%
OM growth 3Y -20.82% OM growth 5Y 8.27%
PM growth 3Y -22.14% PM growth 5Y 12.9%
GM growth 3Y -12.06% GM growth 5Y 3.47%
F-Score 7 Asset Turnover 1.07

Health
Industry RankSector Rank
Debt/Equity 0.44
Debt/FCF 5.41
Debt/EBITDA 1.47
Cap/Depr 128.54%
Profit Quality 46.47%
Current Ratio 3.81
Quick Ratio 2.26
Altman-Z 2.73
F-Score 7 WACC 9.14%
ROIC/WACC 1.41 Cap/Depr(3y) 112.29%
Cap/Depr(5y) 121.24% Profit Quality(3y) 104.64%
Profit Quality(5y) 87.63%

Growth
EPS 1Y 72.15% EPS 3Y -17.89%
EPS 5Y 22.87% EPS growth Q2Q -41.94%
EPS Next Y -1.75% EPS Next 2Y -36.06%
EPS Next 3Y 5.83% EPS Next 5Y N/A
Revenue growth 1Y 12.13% Revenue growth 3Y 5.28%
Revenue growth 5Y 7.29% Revenue growth Q2Q -8.04%
Revenue Next Year 4.44% Revenue Next 2Y -4%
Revenue Next 3Y -1.34% Revenue Next 5Y N/A
EBIT growth 1Y 32.22% EBIT growth 3Y -16.64%
EBIT growth 5Y 16.16% EBIT Next Year 27.46%
EBIT Next 3Y 14.2% EBIT Next 5Y N/A
FCF growth 1Y 117.07% FCF growth 3Y 3.81%
FCF growth 5Y 32.22% OCF growth 1Y 50.76%
OCF growth 3Y 3.09% OCF growth 5Y 18.17%

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA